The inhaled vaccine being researched by CanSino is based on its Convidecia adenovirus vector vaccine for Covid-19. -CANSINOTECH.COM
BEIJING (China Daily/Asia News Network): An inhaled Covid-19 vaccine developed by Chinese firm CanSino Biologics has entered late-stage clinical trials, with data suggesting it is eligible to apply for emergency use in China, the company's chief scientist said.
Zhu Tao, a member of the Chinese People's Political Consultative Conference National Committee, said future Covid-19 vaccination may replace the "jab" with a "huff", and that the procedure is as simple as "sipping a cup of coffee".
Already a subscriber? Log in.
Save 30% for ads-free and full access now!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
